Table 3.

Cognitive impairment assessed through paced auditory serial addition test (PASAT)

Measure	Placebo treatment (n = 14)			um-PEA treatment (n = 15)
	1 month	6 months	12 months	1 month	6 months	12 months
PASAT 3"	35.5 ± 12.8	31.7 ± 17.8	41.1 ± 11.8	36.3 ± 13.6	38.7 ± 11.2	40.9 ± 10.9
PASAT 2"	34.5 ± 14.8	33.7 ± 18.3	36.5 ± 11.7	31.2 ± 12.7	36.9 ± 11.2	41.1 ± 11.2

Results are reported as mean ± SD. Differences between ultramicronized palmitoylethanolamide (um-PEA) and placebo groups were not significant